Last month, 2 Bridge welcomed two new colleagues to strengthen our venture building and CMC team. As part of the “2 Bridge Insights” series, we pulled together those two forward-thinking experts from small molecules, ATMP, venture building perspectives to share their insights on the current CMC (chemistry, manufacturing, and controls) challenges, adaptation, and solutions for developing drug products.
The discussion took place between @ SANDRIEN JANSSENS, our R&D Director CMC, and our VP for Product Development @DANIEL GAU.
In this interview, you will learn:
- Why those two healthcare leaders decided to join us
- Experts’ insights on the current CMC challenges and recommendations for life science companies
- How 2 Bridge can help ensure the quality and consistency of your drug products